J Small Anim Pract. 2021 Dec 14; doi: 10.1111/jsap.13461. Epub 2021 Dec 14.

Angiotensin-converting enzyme inhibitors in preclinical myxomatous mitral valve disease in dogs: systematic review and meta-analysis.

The Journal of small animal practice

P Donati, A Tarducci, R Zanatta, N Verdier, G Belerenian, I Cordero, C Villalta, J Franco, L Tarragona

PMID: 34905219 DOI: 10.1111/jsap.13461

Abstract

To determine the efficacy and adverse events of the administration of angiotensin-converting enzyme inhibitors for the management of preclinical myxomatous mitral valve disease in dogs. A comprehensive search using Pubmed/MEDLINE, LILACS and CAB abstracts databases was performed. Randomised clinical trials that assessed efficacy and adverse events of angiotensin-converting enzyme inhibitors for the management of preclinical myxomatous mitral valve disease in dogs were included. Certainty of evidence was rated using GRADE methods. Four randomised clinical trials were included. While safe, angiotensin-converting enzyme inhibitors administration to dogs with myxomatous mitral valve disease and cardiomegaly results in little to no difference in the risk of development congestive heart failure (high certainty of evidence; relative risk: 1.03; 95% confidence interval: 0.87 to 1.23) and may result in little to no difference in cardiovascular-related (low certainty of evidence; relative risk: 1.01; 95% confidence interval: 0.54 to 1.89) and all-cause mortality (low certainty of evidence; relative risk: 0.93; 95% confidence interval: 0.63 to 1.36). Administration of angiotensin-converting enzyme inhibitors to dogs with myxomatous mitral valve disease without cardiomegaly may result in a reduced risk of congestive heart failure development. However, the range in which the actual effect for this outcome may be, the "margin of error," indicates it might also increase the risk of congestive heart failure development (low certainty of evidence; relative risk: 0.86; 95% confidence interval: 0.54 to 1.35). Administration of angiotensin-converting enzyme inhibitors to dogs with preclinical myxomatous mitral valve disease and cardiomegaly results in little to no difference in the risk of the development of congestive heart failure and may result in little to no difference in cardiovascular-related and all-cause mortality. The certainty of evidence of the efficacy of angiotensin-converting enzyme inhibitors administration to dogs without cardiomegaly was low.

© 2021 British Small Animal Veterinary Association.

References

1. Ames, M. K., Atkins, C. E. & Pitt, B. (2019) The renin-angiotensin-aldosterone system and its suppression. Journal of Veterinary Internal Medicine 33, 363-382 - PubMed
2. Atkins, C. E., Brown, W. A., Coats, J. R., et al. (2002) Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation. Journal of the American Veterinary Medical Association 221, 654-658 - PubMed
3. Atkins, C. E., Keene, B. W., Brown, W. A., et al. (2007) Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. Journal of the American Veterinary Medical Association 231, 1061-1069 - PubMed
4. Atkins, C., Bonagura, J., Ettinger, S., et al. (2009) ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine 23, 1142-1150 - PubMed
5. Baumgartner, H., Falk, V., Jeroen Bax, J. J., et al. (2017) 2017 ESC/EACTS guidelines for the management of valvular heart disease. Revista Española de Cardiología (English Ed) 71, 110 - PubMed
6. Borgarelli, M. & Haggstrom, J. (2010) Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy. The Veterinary Clinics of North America. Small Animal Practice 40, 651-663 - PubMed
7. Borgarelli, M., Ferasin, L., Lamb, K., et al. (2020) Delay of appearance of symptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril: the DELAY study. Journal of Veterinary Cardiology 27, 34-53 - PubMed
8. Boswood, A., Häggström, J., Gordon, S. G., et al. (2016) Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study - a randomized clinical trial. Journal of Veterinary Internal Medicine 30, 1765-1779 - PubMed
9. Deeks, J. J., Higgins, J. P. T. & Altman, D. G. (2019) Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, Vol. 2011. John Wiley & Sons, Ltd, Hoboken, New Jersey handbook.cochrane.org - PubMed
10. Dell'italia, L. J., Balcells, E., Meng, Q. C., et al. (1997) Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. The American Journal of Physiology 273, H961-H970 - PubMed
11. Di Marcello, M., Terzo, E., Locatelli, C., et al. (2014) Assessment of mitral regurgitation severity by Doppler color flow mapping of the vena contracta in dogs. Journal of Veterinary Internal Medicine 28, 1206-1213 - PubMed
12. Fox, P. (2012) Pathology of myxomatous mitral valve disease in the dog. Journal of Veterinary Cardiology 14, 103-126 - PubMed
13. Guyatt, G. H., Oxman, A. D., Vist, G. E., et al. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924-926 - PubMed
14. Haggstrom, J., Duelund Pedersen, H. & Kvart, C. (2004) New insights into degenerative mitral valve disease in dogs. The Veterinary Clinics of North America. Small Animal Practice 34, 1209-1226 - PubMed
15. Häggström, J., Boswood, A., O'Grady, M., et al. (2013) Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study. Journal of Veterinary Internal Medicine 27, 1441-1451 - PubMed
16. Harris, K. M., Aeppli, D. M. & Carey, C. F. (2005) Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity. American Heart Journal 150, 1106-1106.e6 - PubMed
17. Higgins, J. P. T., Altman, D. G. & Sterne, J. A. C. (2011) Chapter 8: assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Eds J. P. T. Higgins and S. Green. John Wiley & Sons, Ltd, Hoboken, New Jersey handbook.cochrane.org - PubMed
18. Higgins, J. P. T., Thomas, J., Chandler, J., et al. (2020) Cochrane Handbook for Systematic Reviews of Interventions Version 6.1. John Wiley & Sons, Ltd, Hoboken, New Jersey www.training.cochrane.org/handbook - PubMed
19. Hooijmans, C. R., Rovers, M. M., de Vries, R. V., et al. (2014) SYRCLEs risk of bias tool for animal studies. BMC Medical Research Methodology 26, 43 - PubMed
20. Keene, B., Atkins, C., Bonagura, J., et al. (2019) ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine 33, 1127-1140 - PubMed
21. Kitagawa, H., Wakamiya, H., Kitoh, K., et al. (1997) Efficacy of monotherapy with benazepril, an angiotensin converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency. The Journal of Veterinary Medical Science 59, 513-520 - PubMed
22. Kvart, C., Häggström, J., Pedersen, H. D., et al. (2002) Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. Journal of Veterinary Internal Medicine 16, 80-88 - PubMed
23. López-Alvarez, J., Elliott, J., Pfeiffer, D., et al. (2015) Clinical severity score system in dogs with degenerative mitral valve disease. Journal of Veterinary Internal Medicine 29, 575-581 - PubMed
24. Moher, D., Shamseer, L., Clarke, M., et al. (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 4, 1 - PubMed
25. Nishimura, R. A., Otto, C. M., Bonow, R. O., et al. (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 63, 2438-2488 - PubMed
26. Olsen, L. H., Fredholm, M. & Pedersen, H. D. (1999) Epidemiology and inheritance of mitral valve prolapse in dachshunds. Journal of Veterinary Internal Medicine 13, 448-456 - PubMed
27. Ouzzani, M., Hammady, H., Fedorowicz, Z., et al. (2016) Rayyan-a web and mobile app for systematic reviews. Systematic Reviews 5, 210 - PubMed
28. Pouchelon, J. L., Jamet, N., Gouni, V., et al. (2008) Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases. Journal of Veterinary Internal Medicine 22, 905-914 - PubMed
29. Serfass, P., Chetboul, V., Sampedrano, C. C., et al. (2006) Retrospective study of 942 small-sized dogs: prevalence of left apical systolic heart murmur and left-sided heart failure, critical effects of breed and sex. Journal of Veterinary Cardiology 8, 11-18 - PubMed
30. Swenson, L., Haggstrom, J., Kvart, C., et al. (1996) Relationship between parental cardiac status in cavalier king Charles spaniels and prevalence and severity of chronic valvular disease in offspring. Journal of the American Veterinary Medical Association 208, 2009-2012 - PubMed
31. Tischler, M. D., Rowan, M. & LeWinter, M. (1998) Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse. The American Journal of Cardiology 82, 242-245 - PubMed

Publication Types

• Journal Article
• Review